Literature DB >> 33505392

Milestones in Personalized Medicine in Pemphigus and Pemphigoid.

Katja Bieber1, Khalaf Kridin1, Shirin Emtenani1, Katharina Boch2, Enno Schmidt1,2, Ralf J Ludwig1,2.   

Abstract

Pemphigus and pemphigoid diseases are autoimmune bullous diseases characterized and caused by autoantibodies targeting adhesion molecules in the skin and/or mucous membranes. Personalized medicine is a new medical model that separates patients into different groups and aims to tailor medical decisions, practices, and interventions based on the individual patient`s predicted response or risk factors. An important milestone in personalized medicine in pemphigus and pemphigoid was achieved by verifying the autoimmune pathogenesis underlying these diseases, as well as by identifying and cloning several pemphigus/pemphigoid autoantigens. The latter has become the basis of the current, molecular-based diagnosis that allows the differentiation of about a dozen pemphigus and pemphigoid entities. The importance of autoantigen-identification in pemphigus/pemphigoid is further highlighted by the emergence of autoantigen-specific B cell depleting strategies. To achieve this goal, the chimeric antigen receptor (CAR) T cell technology, which is used for the treatment of certain hematological malignancies, was adopted, by generating chimeric autoantigen receptor (CAAR) T cells. In addition to these more basic science-driven milestones in personalized medicine in pemphigus and pemphigoid, careful clinical observation and epidemiology are again contributing to personalized medicine. The identification of clearly distinct clinical phenotypes in pemphigoid like the non-inflammatory and gliptin-associated bullous pemphigoid embodies a prominent instance of the latter. We here review these exciting developments in basic, translational, clinical, and epidemiological research in pemphigus and pemphigoid. Overall, we hereby aim to attract more researchers and clinicians to this highly interesting and dynamic field of research.
Copyright © 2021 Bieber, Kridin, Emtenani, Boch, Schmidt and Ludwig.

Entities:  

Keywords:  diagnosis; pemphigoid; pemphigus; precision medicine; treatment

Mesh:

Substances:

Year:  2021        PMID: 33505392      PMCID: PMC7829330          DOI: 10.3389/fimmu.2020.591971

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  103 in total

1.  Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis).

Authors:  Pascal Joly; Noémie Litrowski
Journal:  Clin Dermatol       Date:  2011 Jul-Aug       Impact factor: 3.541

2.  Pemphigus Vulgaris and Pemphigus Foliaceus: Differences in Epidemiology and Mortality.

Authors:  Khalaf Kridin; Shira Zelber-Sagi; Reuven Bergman
Journal:  Acta Derm Venereol       Date:  2017-10-02       Impact factor: 4.437

3.  HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.

Authors:  Hideyuki Ujiie; Ken Muramatsu; Taisei Mushiroda; Takeshi Ozeki; Hideaki Miyoshi; Hiroaki Iwata; Akinobu Nakamura; Hiroshi Nomoto; Kyu Yong Cho; Norihiro Sato; Machiko Nishimura; Takamasa Ito; Kentaro Izumi; Wataru Nishie; Hiroshi Shimizu
Journal:  J Invest Dermatol       Date:  2017-12-02       Impact factor: 8.551

4.  Pemphigus in Hartford County, Connecticut, from 1972 to 1977.

Authors:  D G Simon; D Krutchkoff; R A Kaslow; R Zarbo
Journal:  Arch Dermatol       Date:  1980-09

Review 5.  Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Francesca Cianfarani; Giovanna Zambruno; Daniele Castiglia; Teresa Odorisio
Journal:  Am J Pathol       Date:  2017-04-29       Impact factor: 4.307

6.  Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.

Authors:  K Skandalis; M Spirova; G Gaitanis; A Tsartsarakis; I D Bassukas
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-04-06       Impact factor: 6.166

7.  Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients.

Authors:  M L Lombardi; O Mercuro; V Ruocco; A Lo Schiavo; V Lombari; V Guerrera; G Pirozzi; C Manzo
Journal:  J Invest Dermatol       Date:  1999-07       Impact factor: 8.551

Review 8.  Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.

Authors:  Enno Schmidt; Volker Spindler; Rüdiger Eming; Masayuki Amagai; Frank Antonicelli; John F Baines; Meriem Belheouane; Philippe Bernard; Luca Borradori; Marzia Caproni; Giovanni Di Zenzo; Sergei Grando; Karen Harman; Marcel F Jonkman; Hiroshi Koga; Ralf J Ludwig; Andrew P Kowalczyk; Eliane J Müller; Wataru Nishie; Hendri Pas; Aimee S Payne; Christian D Sadik; Allan Seppänen; Jane Setterfield; Hiroshi Shimizu; Animesh A Sinha; Eli Sprecher; Michael Sticherling; Hideyuki Ujiie; Detlef Zillikens; Michael Hertl; Jens Waschke
Journal:  J Invest Dermatol       Date:  2017-04-05       Impact factor: 8.551

9.  Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.

Authors:  Christian M Karsten; Tina Beckmann; Maike M Holtsche; Jenny Tillmann; Sabrina Tofern; Franziska S Schulze; Eva Nina Heppe; Ralf J Ludwig; Detlef Zillikens; Inke R König; Jörg Köhl; Enno Schmidt
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

Review 10.  CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.

Authors:  Sherly Mardiana; Saar Gill
Journal:  Front Oncol       Date:  2020-05-06       Impact factor: 6.244

View more
  4 in total

Review 1.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

Review 2.  Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?

Authors:  Roberto Maglie; Maria Efenesia Baffa; Francesca Montefusco; Carlo Pipitò; Stefano Senatore; Marco Capassoni; Vincenza Maio; Marco Matucci Cerinic; Emiliano Antiga; Serena Guiducci
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 3.  Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.

Authors:  Piyu Parth Naik
Journal:  J Transl Autoimmun       Date:  2022-04-16

Review 4.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.